Stockscreener 앱 받기
1.7601
17.23%
0.2501
전일 마감가:
$1.51
열려 있는:
$1.65
하루 거래량:
23.36M
Relative Volume:
35.58
시가총액:
$40.21M
수익:
-
순이익/손실:
$-8.32M
주가수익비율:
-3.6547
EPS:
-0.4816
순현금흐름:
$-7.43M
1주 성능:
+9.27%
1개월 성능:
+41.61%
6개월 성능:
+40.48%
1년 성능:
+3.51%
1일 변동 폭
$1.60
$1.82
1주일 범위
$1.44
$1.80
52주 변동 폭
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
명칭
NanoViricides Inc
전화
203-937-6137
주소
1 Controls Drive, Shelton, CT
Compare NNVC vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.765 | 34.40M | 0 | -8.32M | -7.43M | -0.4816 |
VRTX
Vertex Pharmaceuticals Inc
|
444.45 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.70 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
830.77 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.69 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.29 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-16 | 개시 | Alliance Global Partners | Buy |
| 2015-02-11 | 개시 | Midtown Partners | Strong Buy |
NanoViricides Inc 주식(NNVC)의 최신 뉴스
Rare Ebola strain has no treatment; NanoViricides lines up oral NV-387 - Stock Titan
Shelton biotech NanoViricides raises $2M in stock offering - Hartford Business Journal
A. G. P. Maintains Nanoviricides(NNVC.US) With Buy Rating, Maintains Target Price $6 - Moomoo
NanoViricides Highlights NV-387 Strategy for Ebola Outbreak - TipRanks
NanoViricides Completes $2 Million Registered Direct Offering - TipRanks
NanoViricides Raises $2 Million in Registered Direct Offering With Common and Pre-Funded Warrants - TradingView
Market movers: Amer Sports, Tiziana Life Sciences, Ideal Power, NanoViricides... - Proactive financial news
NanoViricides Raises $2 Million in Registered Direct Offering to Advance Broad-Spectrum Antiviral Drug - citybuzz -
NanoViricides closes $2M direct offering - Yahoo! Finance Canada
NNVC stock up 17% today: What’s driving the rally? - MSN
NanoViricides, Inc - Reuters
NanoViricides Announces Closing of ~$2 Million Registered Direct Offering - ACCESS Newswire
Antiviral developer NanoViricides secures $2M from single institutional investor - Stock Titan
NanoViricides Highlights Broad-Spectrum Antiviral Candidate Amid Ebola Outbreak - citybuzz -
NNVC Stock Up 17% Today: What’s Driving The Rally? - Stocktwits
NanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreak - Yahoo! Finance Canada
New Ebola strain has no treatment — NanoViricides highlights oral NV-387 - Stock Titan
About Us - FinancialContent
NanoViricides Prices $2 Million Registered Direct Offering - citybuzz -
NanoViricides Advances NV-387 Toward Phase II Trials for MPox in DRC, Expands Orphan Drug Strategy - citybuzz -
NanoViricides to raise $2M in registered direct offering - Yahoo! Finance Canada
NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering - ACCESS Newswire
Clinical-stage antiviral firm NanoViricides prices $2M stock-and-warrant deal - Stock Titan
NanoViricides, Inc. Has Filed its Quarterly ReportNV-387 Advancing for Phase II - Lelezard
Broad antiviral NV-387 drug candidate targets measles, mpox, smallpox - Stock Titan
NANOVIRICIDES, INC. 3Q FY2026: Net loss $(1.99M), EPS $(0.09) — 10-Q Summary - TradingView
NanoViricides: Fiscal Q3 Earnings Snapshot - marketscreener.com
NanoViricides, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026 - marketscreener.com
NNVC Stock Chart | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
NNVC Stock Price, Quote & Chart | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
TradingKey - TradingKey
NanoViricides Highlights Broad-Spectrum Antiviral Candidate After Andes Hantavirus Incident on Cruise Ship - citybuzz -
Small cap wrap: Gunnison Copper, Graphene Manufacturing Group, NanoViricides… - Proactive financial news
NanoViricides says hantavirus incident highlights need for antiviral drugs - TipRanks
Does the Recent Hantavirus Outbreak Highlight a Critical Gap for NanoViricides' NV-387 - Kavout
NanoViricides says Phase I antiviral drug could address gap exposed by hantavirus cruise ship outbreak - Yahoo Finance
Cruise ship hantavirus deaths spark call for broad-spectrum antiviral drugs - Stock Titan
NanoViricides' NV-387 shows promise as broad antiviral amid deadly hantavirus cruise ship outbreak - Pluang
What NanoViricides (NNVC) bond yields suggest about risk | Q1 2026: Earnings Beat EstimatesCommunity Chart Signals - newser.com
NNVC (NanoViricides) shares surge 9% as EPS beat targets by 23%, defying analyst expectations despite ongoing losses.Spin Off - newser.com
NanoViricides to Present at D. Boral Capital Global Conference as Lead Drug Candidate Advances Toward Phase II Trials - citybuzz -
NanoViricides to Present at D. Boral Capital Global Conference - HarianBasis.co
NanoViricides (NNVC) Secures FDA Orphan Drug Status for NV-387 Measles Treatment - Insider Monkey
NanoViricides to Participate at D. Boral Capital Global Conference in NYC - Yahoo Finance
NanoViricides to present at D. Boral Capital Global Conference May 7 in NYC - Pluang
NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference - Oil & Gas 360
NanoViricides to attend D Boral Capital Conference - Proactive financial news
NanoViricides management offers investor meetings in New York May 7 - Stock Titan
NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDA - Yahoo Finance
NanoViricides’ NV-387 Receives FDA Orphan Drug Designation for Measles Treatment - MEXC
NanoViricides Inc (NNVC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.67%
1.91%
자본화:
|
볼륨(24시간):